,trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['brca']
oh snap!! dr. lorusso quoting in closing remarks following her discussion of the #destiny trial outlining os benefits of #her2-directed therapy for low her2+ #brca expertly presented by dr. shanu modi during #asco22 plenary! 
MD-PhD; Radiation oncologist with a passion for health equity; addressing health literacy; loving patients & advocates; empowering individuals & communities.